These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Neuroleptic malignant syndrome: a review of literature]. Crespo Facorro B; Carbonell Masia C Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(5):273-8. PubMed ID: 8553925 [TBL] [Abstract][Full Text] [Related]
6. The neuroleptic malignant syndrome. Caroff SN J Clin Psychiatry; 1980 Mar; 41(3):79-83. PubMed ID: 6101595 [TBL] [Abstract][Full Text] [Related]
7. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. Aruna AS; Murungi JH Ann Pharmacother; 2005 Jun; 39(6):1131-5. PubMed ID: 15840734 [TBL] [Abstract][Full Text] [Related]
8. The neuroleptic malignant syndrome. Schrader G; Wong C; Russell R; Goldney RD Med J Aust; 1981 Oct; 2(9):494. PubMed ID: 6119606 [TBL] [Abstract][Full Text] [Related]
9. [Pathophysiology and therapy of malignant neuroleptic syndrome]. Weller M; Kornhuber J Nervenarzt; 1992 Nov; 63(11):645-55. PubMed ID: 1361662 [TBL] [Abstract][Full Text] [Related]
10. Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. Harsch HH J Clin Psychiatry; 1987 Aug; 48(8):328-33. PubMed ID: 2886491 [TBL] [Abstract][Full Text] [Related]
11. Detection and management of the neuroleptic malignant syndrome. Bond WS Clin Pharm; 1984; 3(3):302-7. PubMed ID: 6145537 [TBL] [Abstract][Full Text] [Related]
12. [The neuroleptic malignant syndrome (NMS). A report of a clinical case with a protracted and recurrent course. A review of the literature]. Marelli A; Bodini P; Dizioli P; Chiodelli G; Guarneri M; Boldori L Minerva Med; 1996; 87(1-2):45-51. PubMed ID: 8610025 [TBL] [Abstract][Full Text] [Related]
13. The neuroleptic malignant syndrome. A priority system. Neppe VM S Afr Med J; 1984 Mar; 65(13):523-5. PubMed ID: 6143410 [TBL] [Abstract][Full Text] [Related]
14. Neuroleptic malignant syndrome: a case report. Fekadu A; Wakwoya A Ethiop Med J; 1999 Jul; 37(3):195-8. PubMed ID: 11957317 [TBL] [Abstract][Full Text] [Related]
15. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Tsai JH; Yang P; Yen JY; Chen CC; Yang MJ Pharmacotherapy; 2005 Aug; 25(8):1156-9. PubMed ID: 16207109 [TBL] [Abstract][Full Text] [Related]
16. [Malignant neuroleptic syndrome. A review of epidemiology, risk factors, diagnosis, differential diagnosis and pathogenesis of MNS]. Andreassen MD; Pedersen S Ugeskr Laeger; 2000 Mar; 162(10):1366-70. PubMed ID: 10745673 [TBL] [Abstract][Full Text] [Related]
18. Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. Sokoro AA; Zivot J; Ariano RE Ann Pharmacother; 2011 Sep; 45(9):e50. PubMed ID: 21878660 [TBL] [Abstract][Full Text] [Related]
19. Neuroleptic malignant syndrome: a review and report of six cases. Kasantikul D; Kanchanatawan B J Med Assoc Thai; 2006 Dec; 89(12):2155-60. PubMed ID: 17214072 [TBL] [Abstract][Full Text] [Related]